EGFR and obesity due to melanocortin 4 receptor deficiency: Thus, consistent with reports in models of diabetes, this study also demonstrated a harmful effect of EGFR activation in the pathogenesis of obesity-induced cardiac pathology (Li et al., 2016) and thus, potential use of EGFR inhibitors for the treatment for obesity-related cardiovascular complications may be warranted.